How should an 11-year-old with post‑COVID myocarditis be managed?

Management of Post-COVID Myocarditis in an 11-Year-Old

An 11-year-old with post-COVID myocarditis requires immediate hospital admission with cardiology consultation, serial cardiac monitoring including ECGs every 48 hours, echocardiography at presentation and repeated at 7-14 days and 4-6 weeks, and consideration of immunomodulatory therapy with methylprednisolone or IVIG based on severity of presentation. 1

Initial Assessment and Monitoring

The child needs urgent hospitalization for comprehensive cardiac evaluation. Based on ACR guidance for MIS-C (which shares features with post-COVID myocarditis), the following monitoring is essential 1:

• ECG monitoring: Obtain baseline ECG and repeat every 48 hours while hospitalized, then at each follow-up visit to detect conduction abnormalities that may develop after initial presentation
• Cardiac biomarkers: Serial troponin T and BNP/NT-proBNP levels to track myocardial injury and guide treatment decisions
• Telemetry: Continuous cardiac monitoring if any conduction abnormalities are present, as electrical abnormalities are increasingly recognized and may develop after initial presentation

At age 11, this patient falls into the demographic more likely to develop myocarditis rather than Kawasaki-like features, as epidemiologic data shows older children preferentially develop myocarditis and shock 1.

Cardiac Imaging Protocol

Echocardiography schedule 1:

• Initial echocardiogram at presentation to assess ventricular function and coronary arteries
• Repeat at 7-14 days post-presentation
• Follow-up at 4-6 weeks
• If cardiac involvement noted acutely, consider additional echocardiogram at 1 year
• More frequent imaging if LV dysfunction or coronary artery abnormalities are present

Cardiac MRI considerations: For patients with moderate-to-severe LV dysfunction, obtain cardiac MRI at 2-6 months post-acute illness to evaluate for myocardial fibrosis and scarring 1. Recent data shows that while most CMR abnormalities improve over time, late gadolinium enhancement (LGE) may persist in 13% of pediatric patients, though clinical outcomes remain favorable 2.

Treatment Approach

Immunomodulatory Therapy

The evidence supports use of glucocorticoids in pediatric COVID-19 myocarditis:

• Methylprednisolone is the most commonly used agent (84.8% in recent pediatric series) and shows weak negative correlation with length of stay, suggesting potential benefit in shortening hospitalization 3
• IVIG is used in 54.5% of cases and may be combined with steroids 3
• Glucocorticoids showed favorable outcomes with 85% survival to discharge in systematic review 4

Treatment initiation depends on severity 1:

• Life-threatening presentations (shock, severe dysfunction): Initiate immunomodulatory treatment early, potentially before complete diagnostic workup
• Non-life-threatening cases: Complete diagnostic evaluation first to avoid potentially harmful therapy in patients without true myocarditis

Supportive Care

For severe presentations with hemodynamic compromise:

• Veno-arterial ECMO is highly effective in fulminant cases, as demonstrated in a 5-year-old with complete AV block who recovered without sequelae after 8 days of ECMO support 5
• VA-ECMO was the most common intervention (35%) in severe cases 6

Common Pitfalls to Avoid

1. Missing coronary artery involvement: Up to 20% of MIS-C patients develop coronary artery dilations or aneurysms, and this can occur even without Kawasaki-like features. All patients require cardiac evaluation regardless of phenotype 1

2. Inadequate follow-up: Long-term complications may include myocardial fibrosis, scarring, and conduction abnormalities. Don't discharge without establishing clear follow-up plan 1

3. Delayed ECG monitoring: Conduction abnormalities may develop after initial presentation, requiring serial ECGs even if initial study is normal 1

4. Premature activity resumption: While most CMR abnormalities resolve (edema resolves completely, LGE declines from 46% to 0% at long-term follow-up), persistent abnormalities like EGE remain common (80% at long-term) 2. Activity restrictions should be individualized based on imaging findings.

Prognosis and Long-Term Monitoring

The prognosis is generally favorable:

• Mortality rate of 7.9% in systematic review 6
• LV function improves rapidly in most patients 1
• Most CMR abnormalities resolve over time, with no documented arrhythmias, heart failure, or cardiac rehospitalizations at median 20-month follow-up 2
• However, 5 of 17 patients in one series reported negative impact on quality of life and mental health 7

Holter monitoring may be needed at clinical follow-up if conduction abnormalities persist 1.

The combination of close cardiac monitoring, appropriate immunomodulatory therapy based on severity, and structured follow-up imaging provides the best framework for managing this condition while minimizing long-term sequelae.